Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The landscape of Hepatitis C virus (HCV) treatment has been transformed by the advent of direct-acting antivirals (DAAs). Among these, the fixed-dose combination of glecaprevir and Pibrentasvir, known as Mavyret, represents a significant therapeutic achievement. This article explores the synergistic action of Pibrentasvir (CAS 1353900-92-1) in this combination therapy and its impact on achieving sustained virologic response (SVR12), with a nod to the suppliers like NINGBO INNO PHARMCHEM CO.,LTD. who make these advancements possible.
Pibrentasvir, as an NS5A inhibitor, targets a critical protein in the HCV replication cycle. When combined with glecaprevir, a potent NS3/4A protease inhibitor, the dual action effectively suppresses viral activity. This combination therapy is particularly noteworthy for its pan-genotypic coverage and its ability to achieve high cure rates across different HCV genotypes and treatment histories. The short duration of treatment, often just 8 weeks for many patients, is a major advantage, improving patient adherence and accessibility.
The success of Mavyret underscores the importance of Pibrentasvir's specific pharmacological properties, including its potent NS5A inhibitor activity and its favorable pharmacokinetic profile. For pharmaceutical companies, Pibrentasvir is not just a finished drug component but also a vital pharmaceutical intermediate. Its reliable supply is crucial for the consistent production of Mavyret and for ongoing research into next-generation HCV treatments. NINGBO INNO PHARMCHEM CO.,LTD. plays a key role in this supply chain, ensuring the availability of high-quality Pibrentasvir for both therapeutic manufacturing and research purposes.
The advancement in HCV treatment, driven by molecules like Pibrentasvir, continues to bring the goal of HCV eradication closer. By understanding the scientific contributions and the supply chain that supports them, we can better appreciate the impact of these pharmaceutical innovations. The consistent supply of essential components like Pibrentasvir is foundational to these efforts, enabling better HCV treatment efficacy and improved patient outcomes worldwide.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
